How to Value a Medical Practice: EBITDA Multiples for Cardiology, Dermatology, and Primary Care

Medical practice valuation is often reduced to one question: “What EBITDA multiple should I use?” That question is understandable. Buyers, sellers, lenders, and advisers all want a quick way to translate practice earnings into value. Yet a cardiology group, a dermatology clinic, and a primary care practice can have very different economics even when they report the same revenue or the same EBITDA. A supportable business valuation does not begin with a generic specialty multiple. It begins with the specific practice: what cash flow is sustainable, what goodwill is transferable, which providers drive revenue, how payer contracts and reimbursement risk affect collections, which assets and liabilities transfer, and whether market evidence is truly comparable.

Quick answer: The value of a medical practice is usually driven by normalized, transferable cash flow. EBITDA and adjusted EBITDA are useful because many buyers, lenders, and appraisers analyze earnings before interest, taxes, depreciation, and amortization. But an EBITDA multiple is only a market approach input. A professional business appraisal should test normalized EBITDA through the income approach, discounted cash flow, market approach evidence, asset approach considerations, and a reconciliation of practice-specific risks.

This article focuses on cardiology, dermatology, and primary care because those specialties commonly appear in physician-practice acquisition conversations. The goal is not to publish unsupported multiple ranges. Public ranges are often incomplete because they may not disclose the transaction date, buyer type, EBITDA definition, rollover equity, earnouts, debt, working capital, physician compensation assumptions, or whether the deal was a platform acquisition, add-on acquisition, hospital affiliation, or local physician-to-physician transaction. The safer and more useful question is: what would make a specific practice deserve a higher, lower, or less certain valuation indication?

For a physician owner preparing for a sale, partner buyout, buy-sell agreement, financing request, litigation support discussion, or adviser review, Simply Business Valuation can prepare a source-supported medical practice business valuation or business appraisal that explains adjusted EBITDA, valuation methods, market evidence, discounted cash flow assumptions, asset approach considerations, and the key risks a buyer or adviser is likely to ask about.

Important note: This article is educational. It is not legal advice, tax advice, healthcare regulatory advice, coding advice, reimbursement consulting, transaction advisory work, or a valuation opinion for any specific medical practice. Healthcare transactions can raise fair market value, commercial reasonableness, Stark Law, Anti-Kickback Statute, and other issues that should be reviewed by qualified healthcare counsel.

Specialty Value-Driver Comparison: Cardiology, Dermatology, and Primary Care

The specialty label matters because it affects services, staffing, reimbursement exposure, patient behavior, assets, and buyer universe. It does not automatically determine value. A well-run primary care group with stable panels and clean data may be more supportable than a procedure-heavy practice with owner dependence, weak records, or payer recoupment concerns. A dermatology practice with cosmetic revenue may require different forecasting than a dermatology practice driven mostly by medical visits. A cardiology group with diagnostic assets may need more capital expenditure analysis than a less equipment-intensive practice.

Specialty	Common value drivers to analyze	Data to request	Common valuation risks
Cardiology	Procedure mix, diagnostic services, imaging or monitoring services where applicable, provider capacity, referral relationships, hospital relationships, payer mix, ancillary services, equipment needs, and scale	Revenue by CPT or service line, payer mix, collections, provider productivity, diagnostic utilization, referral trends, equipment schedules, maintenance contracts, staffing, and compliance documents	Provider dependence, referral concentration, reimbursement changes, equipment intensity, capital expenditure needs, hospital relationship changes, and regulatory sensitivity
Dermatology	Medical dermatology, surgical dermatology, Mohs, pathology, cosmetic procedures, retail products, recurring patient demand, clinician mix, site-level productivity, reputation, and patient acquisition channels	Service-line revenue, visit trends, cosmetic revenue, Mohs or pathology data where relevant, provider schedules, patient recurrence, reviews, referral sources, and quality or registry documentation where relevant	Mix shift, cosmetic cyclicality, provider departure, personal brand dependence, platform-group comparability issues, and assuming private-equity activity equals value
Primary care	Active patient panels, continuity, payer contracts, value-based or capitated arrangements, care teams, clinician stability, access, telehealth, quality metrics, and referral network value	Panel reports, payer contracts, capitation or PMPM reports if applicable, visit volume, clinician productivity, retention, staffing, quality metrics, patient churn, and care coordination costs	Lower procedure intensity, clinician retention, payer contract concentration, reimbursement exposure, data-quality gaps, and underestimating care-coordination costs

The American Academy of Family Physicians describes primary care as continuous, comprehensive, coordinated, accessible, and person- and family-oriented care, which explains why patient-panel stability and clinician continuity can be central to a primary care valuation (American Academy of Family Physicians, 2019). Dermatology has specialty-specific data and quality infrastructure such as the American Academy of Dermatology’s DataDerm registry, which can be relevant to documentation and practice management but is not a valuation multiple source (American Academy of Dermatology, n.d.). Cardiology consolidation research and specialty-society commentary can help explain buyer interest and market context, but those sources do not create a universal cardiology multiple (American College of Cardiology, 2024; Singh et al., 2024).

Why Medical Practice EBITDA Multiples Can Mislead Buyers and Sellers

EBITDA multiples are a shorthand, not a valuation conclusion

An EBITDA multiple is a simple formula: enterprise value divided by EBITDA or adjusted EBITDA. The simplicity is what makes multiples attractive. It is also what makes them dangerous. If the numerator and denominator are not defined consistently, the result can be misleading.

The numerator may represent enterprise value before debt, cash, working capital, excluded assets, retained liabilities, earnouts, rollover equity, seller notes, or transaction costs. A headline value may include contingent consideration that is not paid unless future performance targets are met. It may include rollover equity that exposes the seller to post-closing platform risk. It may assume a normalized level of working capital that the seller must deliver at closing. If the buyer is also requiring the selling physician to sign an employment agreement at a compensation level below or above market, the apparent business price may not be separable from compensation economics without careful analysis.

The denominator can be just as complicated. “EBITDA” might mean reported EBITDA, adjusted EBITDA, trailing twelve-month EBITDA, run-rate EBITDA, pro forma EBITDA, quality-of-earnings EBITDA, or EBITDA after physician-owner compensation normalization. A practice that pays the owner through distributions instead of salary may show higher reported earnings than a practice that pays market compensation to all physicians. A practice that added back recurring billing, compliance, marketing, staffing, or technology costs may be presenting an earnings measure a buyer or appraiser will not accept. Professional valuation standards and frameworks emphasize scope, procedures, assumptions, documentation, and support; an unexplained number pulled from a public article should not be treated as a valuation conclusion (AICPA & CIMA, 2025; National Association of Certified Valuators and Analysts, n.d.).

Specialty labels do not determine value by themselves

A specialty label can influence buyer interest, service-line economics, and risk. It does not substitute for analysis. Cardiology may involve diagnostic and procedural revenue, referral relationships, hospital interactions, Medicare exposure, and equipment needs. Dermatology may blend medical, surgical, cosmetic, pathology, and retail or product revenue. Primary care may depend on patient panels, payer contracts, care teams, and continuity. These differences shape valuation assumptions, but they do not prove a specific multiple.

A procedure-heavy practice can have weak value if billing is unreliable, referral sources are concentrated, a key physician is leaving, or the buyer cannot retain providers. A primary care practice can have meaningful value if it has stable panels, clean records, durable payer contracts, strong clinician retention, and transferable systems. A dermatology practice can be attractive for recurring demand and service-line breadth, yet still require careful analysis if cosmetic revenue is highly cyclical or tied to one provider’s personal brand.

Private-equity acquisition studies in cardiology, dermatology, and primary care show that ownership and consolidation patterns are a real market backdrop (Bartlett et al., 2024; Singh et al., 2024; Tan et al., 2019; Zhu et al., 2026). But consolidation evidence is not the same as valuation evidence for a particular clinic. A public study may identify acquisition activity, affiliation trends, pricing implications, clinician exits, or debt valuation changes. It usually does not give the appraiser the specific transaction terms, adjusted EBITDA definition, working-capital target, provider compensation assumptions, or post-closing employment arrangements needed to select a multiple for a specific practice.

The four questions behind every market multiple

Before relying on any EBITDA multiple, ask four questions.

1. What is being valued? The subject may be the business enterprise, equity, assets, a partial ownership interest, professional goodwill, a management services organization, an ancillary asset, or a compensation arrangement. Each subject can require different analysis.
2. Which EBITDA is being used? Reported EBITDA and normalized EBITDA can differ materially once owner compensation, associate provider economics, rent, nonrecurring expenses, payer adjustments, and recurring support costs are reviewed.
3. Which buyer universe is relevant? Physician buyers, hospitals, strategic groups, private-equity platforms, private-equity add-ons, and local independent buyers may underwrite the same practice differently.
4. Which risks affect transferability? Provider dependence, referral concentration, payer concentration, data quality, growth durability, compliance sensitivity, equipment needs, and staffing stability can change the weight placed on market evidence.

Multiple reliability question	More reliable evidence looks like	Higher-risk evidence looks like
Transaction comparability	Same specialty, similar scale, geography, payer mix, provider model, service lines, and buyer type	Broad healthcare-services multiple with no practice-level detail
EBITDA definition	Adjusted EBITDA reconciled to financial statements and normalized compensation	Seller-provided EBITDA with unsupported add-backs
Deal structure	Clear treatment of debt, cash, working capital, earnouts, rollover equity, and contingent consideration	Headline price with no terms or closing mechanics
Buyer type	Comparable buyer universe and clear strategic rationale	Platform transaction applied to a small solo practice
Transferability	Provider retention, contracts, systems, and goodwill can transfer	Value tied mostly to a departing owner physician
Compliance fit	Healthcare counsel and valuation professional review sensitive arrangements	Assumptions ignore referral-sensitive structures, physician compensation, or payer issues

Define the Valuation Subject Before Doing the Math

Identify the subject interest, valuation date, intended use, and standard of value

A medical practice valuation should define the assignment before calculations begin. The appraiser needs to know whether the assignment concerns a 100 percent equity interest, a partial ownership interest, an asset sale, an enterprise value indication, a partner buyout, a buy-sell agreement, a financing request, an estate or gift planning matter, a divorce matter, a shareholder dispute, or a healthcare transaction requiring special FMV sensitivity. The valuation date matters because payer contracts, provider rosters, revenue-cycle performance, reimbursement policy, staffing, and market conditions change.

Recognized valuation frameworks such as AICPA VS Section 100, NACVA professional standards, USPAP resources, and IVSC materials all point toward a disciplined process: define the engagement, gather relevant data, analyze the subject, select appropriate valuation methods, document assumptions, and communicate limitations (AICPA & CIMA, 2025; International Valuation Standards Council, n.d.; National Association of Certified Valuators and Analysts, n.d.; The Appraisal Foundation, n.d.). The exact standards that apply depend on the appraiser, credential, jurisdiction, intended use, and engagement terms. The practical takeaway for owners is simple: the report should explain what was valued, for whom, as of what date, under what assumptions, and with what limitations.

Separate enterprise value from equity value

EBITDA multiples commonly produce an enterprise value indication. Enterprise value generally reflects the value of the operating business before certain financing and deal-specific adjustments. Equity value is what remains after considering debt, cash, working capital, excluded assets, retained liabilities, and transaction terms.

Medical practices often have equipment loans, lines of credit, accounts receivable, payroll accruals, provider bonus obligations, payer recoupment exposure, lease obligations, software contracts, inventory, supplies, and working-capital needs. A practice with the same enterprise value as another practice can produce very different seller proceeds if one has material equipment debt, weak receivable collectability, or known payer liabilities. For that reason, the valuation report and transaction documents should not blur enterprise value, equity value, cash at closing, and total potential consideration.

Separate business value from physician compensation FMV

Physician compensation is one of the most important EBITDA normalization areas. It is also one of the easiest areas to confuse with a separate compensation fair market value analysis. A business valuation may need a supportable replacement compensation assumption for the clinical and administrative work performed by physician owners. That does not mean the business valuation itself is a legal opinion on whether every compensation arrangement satisfies healthcare regulatory requirements.

Benchmark resources such as MGMA’s provider compensation and financial/operational DataDive products can be relevant to professionals evaluating compensation, productivity, staffing, revenue cycle, and overhead (Medical Group Management Association, n.d.-a, n.d.-b). Public product pages, however, do not provide quotable benchmark values for a specific specialty. A valuation report should either use properly licensed benchmark data, client-specific evidence, or other supportable data sources, and it should explain the assumptions used.

Separate enterprise goodwill from personal goodwill

Medical practice goodwill may include patient records, trained staff, systems, location, trade name, payer relationships, workflows, phone numbers, websites, referral relationships, recurring patient demand, and reputation. Some of that goodwill may be transferable to a buyer. Some may be personal to a physician whose reputation, relationships, or clinical role cannot be fully transferred.

The distinction is practical even when the article is not making a legal conclusion. If revenue depends heavily on one departing physician, a buyer may discount expected cash flow, require retention payments, use an earnout, or reduce reliance on a headline multiple. If the practice has a broad provider team, documented systems, stable patient demand, assignable payer contracts, and management depth, more goodwill may be transferable. Transaction-data resources such as the Goodwill Registry can be useful to professionals researching medical-practice goodwill and transactions, but a public product page does not replace a practice-specific analysis (ValuSource, n.d.).

Build a Normalized EBITDA Foundation

Start with quality financial statements

The first job in medical practice business valuation is not selecting a multiple. It is understanding the numbers. A valuation analyst typically requests several years of tax returns, profit-and-loss statements, balance sheets, general ledgers, monthly revenue and expense trends, payroll reports, provider compensation detail, debt schedules, accounts receivable aging, payer mix, billing and collections reports, write-off reports, denial information, productivity reports, and practice-management system data. The objective is to reconcile the accounting records to the business reality.

Cash-basis tax returns may not show earned but uncollected revenue, accrued expenses, provider bonuses, or true working capital. Management reports may be useful but may not tie cleanly to bank records or tax returns. Practice-management systems may show visits, procedures, charges, collections, write-offs, denials, and payer activity that the financial statements summarize too broadly. A business appraisal is not automatically a quality-of-earnings engagement, coding audit, or reimbursement review, but it still needs enough support to avoid relying on unsupported management numbers.

The Centers for Medicare & Medicaid Services maintains Physician Fee Schedule resources that show Medicare payment policy is a real operating context for physician practices (Centers for Medicare & Medicaid Services, n.d.-b). That does not mean the appraiser can value a practice from a CMS page. The valuation needs the practice’s own payer mix, contracts, collections, coding, denials, and service-line data.

Normalize physician-owner compensation

Physician-owner compensation can swing EBITDA dramatically. Suppose a physician owner takes minimal W-2 compensation and most economics as distributions. Reported EBITDA may look high because the practice has not recorded the full cost of replacing that physician’s clinical and administrative services. Conversely, an owner may run personal, discretionary, or nonrecurring costs through the practice, causing reported earnings to look lower than sustainable earnings. Both situations require careful normalization.

The goal is not to punish or reward a physician for tax planning, compensation structure, or personal spending choices. The goal is to estimate the cash flow a hypothetical buyer could reasonably expect after paying for the labor needed to operate the practice. If the owner performs clinical work, medical director duties, administrative leadership, recruiting, payer contracting, or management oversight, the valuation should address what it would cost to replace those functions or retain the owner after a transaction.

Compensation normalization should be supportable. It may rely on specialty-specific data, productivity measures, employment agreements, actual collections, market compensation evidence, and professional judgment. Public benchmark pages can show that specialized compensation data resources exist, but they do not justify copying unlicensed numbers into a report (Medical Group Management Association, n.d.-a).

Evaluate associate provider economics

Associate physicians, advanced practice providers, locum tenens clinicians, and clinical staff can affect value in two ways. First, they generate revenue. Second, they create cost, retention, and capacity risk. A practice with growing revenue but high provider turnover may have less durable EBITDA than a practice with stable schedules, documented workflows, and a strong retention plan. A new associate may be temporarily unprofitable during ramp-up but valuable once patient volume builds. A provider who appears profitable may rely on one payer contract, one referring physician, or one procedure category.

The labor-market point in valuation is practical: replacing physicians and advanced practice providers can be costly, slow, and uncertain. Recruiting costs, sign-on bonuses, locum coverage, credentialing delays, productivity ramp-up, and provider exits may need to be considered in normalized EBITDA or discounted cash flow scenarios. Specialty-specific compensation and productivity resources may help professionals evaluate these assumptions, but public benchmark pages should not be treated as published replacement-compensation values for a specific practice (Medical Group Management Association, n.d.-a).

Normalize nonrecurring and discretionary items carefully

Common EBITDA adjustments may include one-time legal fees, documented one-time EMR conversion costs, nonrecurring recruiting costs, unusual bad debt, moving costs, owner personal expenses, related-party rent adjustments, or a documented payer settlement that is not expected to recur. Adjustments should be evidence-based. The more aggressive the add-back, the more support it requires.

Some costs should not be added back simply because the seller dislikes them. Recurring marketing, billing staff, compliance support, malpractice insurance, credentialing, EMR subscriptions, equipment maintenance, patient communications, and revenue-cycle management are often necessary to sustain the practice. Removing them can overstate EBITDA. A buyer, lender, or appraiser may reject adjustments that are not nonrecurring, not documented, or not transferable to the buyer’s actual operating model.

Reimbursement, coding, payer mix, and collections affect EBITDA quality

EBITDA quality depends on revenue quality. A practice with clean claims, consistent collections, low denials, stable payer contracts, and well-documented coding may deserve more confidence than a practice with unexplained write-offs, payer disputes, high accounts receivable aging, or unsupported revenue recognition. Payer mix also matters. Medicare, Medicaid, commercial insurance, self-pay, cosmetic cash-pay, employer contracts, capitated arrangements, value-based payments, and direct primary care models may have different collection timing, risk, and forecast requirements.

The valuation should not quote reimbursement rates from a general CMS page unless the exact rate file, date, code, locality, and payment context have been verified. Instead, the appraiser should analyze the practice’s actual revenue and collection data. If a payer contract is expiring, if a major service line is affected by policy changes, or if denials are increasing, historical EBITDA may not represent future cash flow.

EBITDA bridge item	Hypothetical adjustment logic	Direction
Reported practice net income	Starting point from practice financial statements	Baseline
Interest, taxes, depreciation, and amortization	Add back if included in the starting earnings measure	Add back as applicable
Physician-owner replacement compensation	Adjust to reflect supportable compensation for clinical and administrative services	Increase or decrease EBITDA depending on actual pay
Associate provider normalization	Adjust for documented nonrecurring vacancies, ramp-up, unusual compensation, or locum coverage	Case-specific
Nonrecurring legal or EMR conversion cost	Add back only if truly nonrecurring and documented	Potential add-back
Recurring marketing, billing, compliance, and EMR support	Usually required to sustain operations	Usually no add-back
Payer recoupment or billing correction	Adjust if prior revenue was overstated or understated	Case-specific
Rent normalization	Adjust if related-party rent differs from market or lease terms	Case-specific
Normalized EBITDA	Output used in market approach and income approach support	Result

Normalized EBITDA = Reported operating income
                  + Interest, taxes, depreciation, and amortization included in the starting measure
                  + Supportable nonrecurring expenses
                  +/- Physician-owner compensation normalization
                  +/- Associate provider and staffing normalization
                  +/- Rent, payer, billing, and other documented adjustments
                  - Recurring costs required to sustain the practice

Enterprise value indication under the market approach = Normalized EBITDA x M
where M = a source-supported, practice-specific selected market multiple,
not a generic specialty range copied from an internet article.

How Cardiology Practice Valuation Differs

Cardiology value drivers

Cardiology valuation often requires more than a review of revenue and EBITDA. The appraiser may need to understand office visits, diagnostic testing, imaging or monitoring services where applicable, procedure mix, provider capacity, hospital relationships, referral patterns, payer mix, and capital equipment. A cardiology practice may have expensive equipment, maintenance agreements, leasehold needs, and staffing requirements that affect both EBITDA and reinvestment assumptions. If a meaningful share of revenue is tied to a single physician, a single hospital relationship, a narrow referral base, or a small number of payers, the valuation should address concentration risk.

Cardiology has received attention in private-equity and consolidation research. The American College of Cardiology highlighted research describing private equity acquisition as a growing trend in cardiology, and peer-reviewed work has examined private-equity consolidation in cardiovascular care (American College of Cardiology, 2024; Bartlett et al., 2024; Singh et al., 2024). That market backdrop may help explain why buyers ask for clean data and scalable operations. It does not, by itself, support a cardiology EBITDA multiple for a specific practice.

Cardiology diligence questions

A cardiology valuation should usually ask:

• What revenue comes from evaluation and management visits, diagnostics, imaging, remote monitoring, procedures, hospital-related services, ancillaries, or other categories?
• Which providers generate each revenue stream, and what happens if one provider leaves?
• Are referral sources concentrated among a few physicians, hospitals, employers, facilities, or payers?
• Which equipment, leases, service contracts, software, and capital expenditures are required to sustain current revenue?
• Are coding, billing, credentialing, payer contracts, documentation practices, and compliance policies sufficiently documented for a buyer or appraiser to review?
• Are hospital relationships, medical directorships, co-management arrangements, space leases, or other arrangements involved that healthcare counsel should evaluate?

Valuation methods for cardiology

The income approach and discounted cash flow can be important when cardiology revenue depends on procedure volumes, provider capacity, equipment investment, reimbursement assumptions, or referral relationships that may change. The market approach can be useful when the appraiser has genuinely comparable transaction evidence with clear EBITDA definitions and deal terms. The asset approach can matter when diagnostic equipment, leaseholds, working capital, receivables, software, and debt are material. A credible business appraisal reconciles those methods instead of assuming that a specialty name or public multiple range captures all risk.

Hypothetical cardiology mini case study

Consider a hypothetical multi-provider cardiology group with diagnostic services, several advanced practice providers, meaningful equipment, and referral concentration from a small number of sources. Reported EBITDA looks strong, but the owner physicians have taken below-market compensation and one diagnostic line requires upcoming equipment replacement. The practice also has equipment debt and a billing report showing denials increasing for a subset of services.

A professional valuation would first normalize physician-owner compensation and test whether the reported EBITDA remains sustainable. It would analyze provider productivity, referral concentration, payer mix, equipment maintenance, capital expenditure needs, and working capital. A discounted cash flow model could test base, downside, and upside scenarios for volume, reimbursement, provider retention, and equipment reinvestment. Market approach evidence might be used if comparable cardiology transactions are available, but a platform transaction involving a larger group with management infrastructure would not automatically apply to this hypothetical practice. Finally, enterprise value would need to be bridged to equity value after debt, working capital, and transaction-specific adjustments.

How Dermatology Practice Valuation Differs

Dermatology value drivers

Dermatology practices can vary widely. One practice may be mostly medical dermatology. Another may have a large cosmetic component. Another may include Mohs surgery, pathology relationships, retail products, multiple sites, or provider-specific brands. A valuation should analyze revenue by service line, provider, site, payer, and patient segment where possible. Recurring patient demand, scheduling capacity, clinician mix, reputation, patient acquisition channels, cosmetic cyclicality, and provider retention can all affect sustainable EBITDA.

The American Academy of Dermatology describes DataDerm as a clinical data registry built by dermatologists for dermatologists, used for clinical insights, quality reporting, and advancing treatment (American Academy of Dermatology, n.d.). That is useful context for documentation and data discipline in dermatology. It is not a valuation multiple source. Similarly, dermatology private-equity acquisition research supports the existence of consolidation and PE-backed dermatology management groups, but it does not tell an owner what a local practice is worth (Agarwal & Orlow, 2024; Tan et al., 2019).

Dermatology private-equity context

Dermatology has been a visible area of physician-practice consolidation. Peer-reviewed dermatology literature has discussed private-equity-backed dermatology practice acquisitions, and a separate open-access study examined debt valuations of private-equity-backed dermatology groups before and during the COVID-19 pandemic (Memon et al., 2022; Tan et al., 2019). These sources should be used carefully. Debt valuation changes for PE-backed dermatology groups are not the same as fair market value of an independent dermatology practice. Acquisition trends do not mean every dermatology practice will receive platform-level buyer interest or a particular EBITDA multiple.

For valuation, the relevant question is not “Did PE buy dermatology practices?” The relevant question is “What does this practice’s revenue, EBITDA, provider team, service mix, documentation, payer exposure, patient demand, and transferability support?”

Dermatology diligence questions

A dermatology valuation should usually ask:

• What percentage of revenue comes from medical dermatology, surgical dermatology, Mohs, pathology, cosmetic procedures, retail products, and other services?
• Are cosmetic revenues recurring and transferable, or dependent on one provider’s brand and patient following?
• How stable are provider capacity, appointment availability, patient demand, and payer mix?
• Which providers perform the highest-margin procedures, and are they staying after a transaction?
• Are patient reviews, digital marketing assets, referral sources, and online reputation important to revenue, and are those assets controlled by the practice?
• Are coding, billing, pathology relationships, cosmetic consent processes, and compliance documents available for review?

Hypothetical dermatology mini case study

Consider a hypothetical two-location dermatology practice with medical dermatology, Mohs referrals, a growing cosmetic service line, and one highly visible owner physician. The financial statements show attractive EBITDA, but service-line data reveals that cosmetic revenue is concentrated in one location and one provider. Medical dermatology demand is stable, but a new associate is still ramping up. The practice’s online reputation and patient communications system are valuable, but many patient relationships are tied to the owner’s name.

A professional valuation would separate service-line economics, normalize owner compensation, test cosmetic revenue durability, analyze provider retention, review patient recurrence, and evaluate whether the practice’s goodwill is transferable. The discounted cash flow might include a downside scenario for cosmetic demand and provider transition. The market approach might consider dermatology transaction evidence only if it matches the practice’s size, service mix, buyer type, and EBITDA definition. The asset approach would still review equipment, supplies, working capital, software, leaseholds, and liabilities.

How Primary Care Practice Valuation Differs

Primary care value drivers

Primary care value often depends less on procedure intensity and more on continuity, access, panel stability, payer contracts, care teams, clinician retention, quality programs, and data quality. AAFP’s description of primary care emphasizes comprehensive, first-contact, continuing, coordinated, accessible, and high-value care (American Academy of Family Physicians, 2019). Those characteristics shape valuation. A buyer may care about whether patients are assigned to the practice, whether payer contracts are transferable, whether value-based care revenue is documented, whether clinicians are staying, and whether care coordination costs have been properly captured.

Primary care may include fee-for-service visits, capitated revenue, Medicare Advantage arrangements, shared savings, employer contracts, direct primary care fees, chronic care management, telehealth, or other revenue models. Each model can require different forecasting. The valuation should not assume that all patient panels produce the same value. Panel size, churn, payer mix, attribution rules, quality metrics, coding, risk adjustment, access, and clinician availability all matter.

Consolidation, pricing, and workforce context

Primary care has also been studied in relation to hospital affiliation, private equity, pricing, and clinician workforce dynamics. A PubMed-indexed JAMA Health Forum study describes research on hospital and private-equity consolidation in primary care and price implications, while a Health Affairs study summarized in PubMed examined workforce changes after private-equity acquisition of primary care practices (Singh et al., 2025; Zhu et al., 2026). These sources are market context, not valuation multiples.

For a valuation analyst, clinician exits and staffing stability matter because they can affect access, patient continuity, revenue forecasts, and replacement costs. Pricing or affiliation research may help explain why buyers pay attention to payer contracts, but it does not establish a transaction multiple for a specific practice.

Primary care diligence questions

A primary care valuation should usually ask:

• What is the active patient panel, and how is it measured?
• How many patients are assigned under value-based, capitated, Medicare Advantage, commercial, employer, or direct primary care arrangements if applicable?
• Which payer contracts are transferable, assignable, or subject to consent?
• What portion of revenue depends on a physician-owner who may retire or reduce clinical time?
• Are clinicians and advanced practice providers likely to stay after a transaction?
• Are quality metrics, coding, risk adjustment, care coordination, chronic care management, and shared-savings assumptions documented?
• Are care coordination costs and administrative staffing properly reflected in EBITDA?

Hypothetical primary care mini case study

Consider a hypothetical primary care group with a stable patient panel, mixed fee-for-service and value-based contracts, strong patient retention, and recent clinician turnover. Reported EBITDA is modest compared with more procedure-heavy specialties, but the practice has durable patient relationships, consistent visit volume, and payer contracts that may be attractive to the right buyer. The risk is that two clinicians may leave unless employment terms are addressed.

A professional valuation would analyze panel stability, clinician retention, payer contract durability, care coordination costs, revenue by payer model, and the quality of data supporting value-based revenue. A discounted cash flow model could test scenarios for clinician retention, patient churn, payer contract renewal, staffing costs, and shared-savings assumptions. The market approach would be used only if comparable primary care transactions are available with similar payer arrangements and EBITDA definitions. The asset approach would address working capital, receivables, equipment, software, and liabilities.

Choosing the Right Valuation Methods for a Medical Practice

Income approach and discounted cash flow

The income approach values a business based on expected future economic benefits. For medical practices, this often means forecasting revenue, expenses, reinvestment, working capital, and risk. A discounted cash flow model can be especially useful when historical EBITDA is not a clean proxy for future performance. That may occur when the practice is adding providers, losing providers, changing payer contracts, adding service lines, expanding locations, replacing equipment, correcting billing issues, or facing reimbursement changes.

A DCF model should be practice-specific. It may forecast patient visits, procedures, service-line mix, provider FTEs, schedule capacity, payer mix, collections, denials, patient retention, provider compensation, clinical staffing, billing, rent, malpractice insurance, EMR costs, marketing, compliance, supplies, equipment maintenance, capital expenditures, and working capital. The model should also explain risk. Unsupported growth rates, discount rates, terminal values, and margin assumptions can make a DCF look precise while reducing credibility.

Market approach

The market approach compares the subject practice to transactions or market data involving similar businesses. In a medical practice valuation, this can include comparable transactions, direct deal evidence, letters of intent, buyer feedback, proprietary databases, or industry reports. The quality of evidence varies. ValuSource’s Goodwill Registry page supports the practical point that professionals use specialized medical-practice goodwill and transaction-data resources, but the public product page does not provide a usable multiple for any specific practice (ValuSource, n.d.).

The market approach is strongest when the appraiser knows the specialty, size, geography, revenue mix, EBITDA definition, buyer type, deal structure, transaction date, working-capital treatment, provider retention terms, and any contingent consideration. It is weakest when a broad public healthcare-services range is applied to a local practice without comparability analysis. Industry commentary can be useful as background; for example, FOCUS Investment Banking discusses adjusted EBITDA and value drivers such as quality of earnings, scale, ancillaries, payer mix, and credible growth in medical practice valuation (FOCUS Investment Banking, 2025). That type of commentary should not be treated as a universal rule or a substitute for a professional business valuation.

Asset approach

The asset approach values the assets and liabilities of the practice. For a profitable going concern, the asset approach may not capture all transferable goodwill, assembled workforce, patient records, payer relationships, systems, trade name, or practice infrastructure. Still, it matters. Medical practices may have equipment, furniture, leasehold improvements, software, receivables, supplies, inventory, debt, accrued payroll, provider bonuses, payer liabilities, and working capital needs.

The asset approach may receive more weight when earnings are weak, the practice is start-up or distressed, the transaction is asset-heavy, or equipment and working capital are central to value. Even when income and market methods dominate, an asset review helps bridge enterprise value to equity value and helps avoid double counting or omitting key assets and liabilities.

Business appraisal reconciliation

A business appraisal should reconcile methods. It should not mechanically average an income approach conclusion, a market approach conclusion, and an asset approach conclusion if the evidence quality differs. The appraiser should explain which method is most relevant, which evidence is most reliable, and why the final conclusion is reasonable. Weighting depends on data quality, practice stage, specialty, financial statement reliability, normalized EBITDA support, transaction comparability, asset intensity, intended use, and standard of value.

Valuation method	When it fits a medical practice	Evidence needed	Common mistake
Income approach	Future cash flow is forecastable and practice-specific assumptions can be supported	Historical financials, payer mix, provider schedules, productivity, staffing, capex, working capital	Treating last year’s EBITDA as automatically sustainable
Discounted cash flow	Growth, reimbursement, provider capacity, and reinvestment needs require explicit scenarios	Forecasts by provider, service line, payer, collections, expenses, capital needs, and risk	Using unsupported growth, discount rate, or terminal value assumptions
Market approach	Comparable transaction evidence is sufficiently similar and well-defined	Transaction databases, LOIs, deal terms, EBITDA definitions, buyer type, specialty comparability	Applying broad healthcare-services multiples to a local practice
Asset approach	Tangible assets, working capital, or weak earnings are important	Equipment schedules, receivables, inventory, software, leases, debt, liabilities	Ignoring intangible going-concern value in a profitable practice
Business appraisal reconciliation	Multiple methods provide useful but imperfect evidence	Source map, assumptions, management interview, report narrative, method weighting	Mechanical averaging or unsupported weighting

Healthcare Regulatory and FMV Considerations That Affect Value

Why healthcare deals are not ordinary small-business deals

A physician practice transaction can involve referrals, designated health services, physician compensation, management services, space or equipment leases, medical directorships, ancillary services, and buyer-seller relationships that do not appear in many ordinary small-business transactions. CMS’s physician self-referral materials describe the Stark Law framework at a high level, and the HHS Office of Inspector General identifies major federal fraud and abuse laws relevant to physicians, including the Anti-Kickback Statute, Stark Law, False Claims Act, Exclusion Authorities, and Civil Monetary Penalties Law (Centers for Medicare & Medicaid Services, n.d.-a; Office of Inspector General, 2021).

The business valuation takeaway is not that an appraiser should provide legal advice. The takeaway is that healthcare counsel may need to review transaction structure, compensation arrangements, management agreements, referral-sensitive relationships, and fair-market-value or commercial-reasonableness issues. A valuation can support a transaction, but it does not make an arrangement compliant by itself.

Fair market value, commercial reasonableness, and valuation scope

For valuation purposes, the important point is that healthcare deals often require careful separation of business value, compensation value, lease value, referral-sensitive value, and commercially reasonable business purpose. CMS materials can provide official background on physician self-referral, but exact legal wording and transaction structure should be confirmed by healthcare counsel because regulatory interpretation is outside the scope of an educational valuation article (Centers for Medicare & Medicaid Services, n.d.-a).

If a buyer pays more than supportable business value because it expects referrals, ancillary volume, or compensation concessions, legal counsel should address the structure. If a valuation assumes revenue that may not be legally or practically transferable, the conclusion may be overstated. If compliance costs are recurring, they should generally be reflected in sustainable EBITDA rather than added back casually.

Compliance-related valuation risk factors

Risk area	Why it matters for valuation	Evidence to request	Drafting guardrail
Provider dependence	Departing physicians can reduce revenue and goodwill transferability	Employment agreements, retention plans, productivity by provider	Avoid assuming all goodwill transfers
Payer concentration	Rate changes, denials, or contract loss can reduce cash flow	Payer mix, contracts, denial reports, write-offs	Do not convert CMS policy into a universal discount
Referral concentration	Referral loss can reduce volume after closing	Referral reports, marketing sources, hospital relationships	Avoid legal conclusions
Coding and documentation	Recoupments or compliance findings can affect normalized EBITDA	Billing audits, coding policies, payer correspondence	A valuation is not a coding audit
Compensation arrangements	Replacement compensation and regulated arrangements can affect EBITDA and compliance review	Provider agreements, productivity, benchmark support	Do not quote proprietary benchmark values without support
Equipment and leases	Debt, maintenance, replacement, and lease terms affect equity value	Equipment list, leases, debt schedules, service contracts	Separate enterprise value from equity value
Data quality	Weak records reduce confidence in EBITDA and the market approach	Practice-management reports, general ledger, tax returns, bank records	Do not rely on unsupported management numbers

Market Approach: How to Use Comparable Transactions Without Copying a Multiple

What qualifies as comparable transaction evidence

Comparable transaction evidence should provide enough information to understand the practice category, specialty, size, revenue, EBITDA definition, buyer type, geography, service-line mix, transaction date, deal terms, and provider retention expectations. A transaction involving a multi-state platform with management infrastructure, acquisition pipeline, and ancillary assets may not be comparable to a two-physician local practice. A physician-to-physician sale may not be comparable to a private-equity recapitalization. A hospital affiliation may not be comparable to a strategic group add-on.

The appraiser may consider proprietary databases, direct transaction data, buyer indications, letters of intent, industry reports, and management interviews. The value of that evidence depends on transparency. A multiple without the underlying EBITDA definition can be worse than no multiple because it can create false confidence.

Platform transactions are not the same as small-practice transactions

Platform groups may receive different buyer interest because of scale, management depth, geographic footprint, payer contracts, ancillaries, add-on acquisition opportunity, systems, and leadership team. Smaller add-on practices may have higher provider dependence, less management infrastructure, more integration risk, and different deal terms. A market approach that ignores that distinction can overstate or understate value.

This is especially important in physician practices because a headline multiple may be tied to rollover equity, employment agreements, management services, earnouts, or contingent payments. A selling physician may see a headline enterprise value but receive only part of that value in cash at closing. Another portion may depend on future performance, continued employment, or the value of a buyer’s platform equity.

Deal structure can change the apparent multiple

A transaction multiple is not just price divided by EBITDA. It is price divided by a particular earnings measure under a particular structure. Consider these deal terms:

• cash at closing;
• seller note;
• earnout;
• rollover equity;
• retained cash;
• assumed or paid-off debt;
• working-capital target;
• excluded real estate;
• equipment leases;
• post-closing employment compensation;
• management services fees;
• payer liabilities;
• transaction expenses.

Each item can change the economics. If a buyer offers a higher headline price but requires a large rollover, uncertain earnout, or below-market physician compensation, the headline multiple may not represent the same value as an all-cash offer with market compensation. A business appraisal should explain what value measure is being reported and what adjustments remain outside the conclusion.

Comparability factor	Why it matters	Cardiology example	Dermatology example	Primary care example
Specialty and services	Revenue mix affects margin, risk, and buyer interest	Diagnostics/procedures vs consults	Medical vs cosmetic vs Mohs	Fee-for-service vs value-based care
Practice scale	Scale affects buyer universe and management depth	Multi-site group vs small office	Platform add-on vs solo clinic	Group practice vs small panel
EBITDA definition	Adjustments affect the denominator	Owner compensation and equipment costs	Provider mix and cosmetic cyclicality	Clinician staffing and care coordination
Payer mix	Rates and collection risk affect cash flow	Medicare/commercial mix	Cash-pay cosmetic exposure	Commercial, Medicare, Medicaid, capitation
Provider retention	Goodwill transferability affects risk	Key cardiologist dependence	Mohs/cosmetic provider dependence	PCP panel continuity
Deal terms	Headline value may not equal seller proceeds	Earnout tied to retention or growth	Rollover equity in platform	Employment retention provisions

Discounted Cash Flow for Medical Practices

Forecasting revenue by practice driver

A discounted cash flow model can provide a more practice-specific view than a generic EBITDA multiple. The model should forecast the drivers that actually create revenue. For cardiology, that may include visit volume, diagnostic testing, procedures, monitoring, provider schedules, payer mix, and equipment capacity. For dermatology, it may include medical visits, surgical services, Mohs, pathology relationships, cosmetic procedures, retail products, patient recurrence, and provider schedules. For primary care, it may include patient panels, fee-for-service visits, capitation, shared savings, quality incentives, telehealth, clinician capacity, and care coordination.

The forecast should be tied to evidence. Historical visits, charges, collections, denial rates, provider productivity, payer contracts, referral trends, patient retention, staffing, and scheduled capacity are more useful than unsupported growth assumptions. If the practice is launching a new service line, the model should separate existing performance from planned expansion.

Forecasting expenses and reinvestment

Medical practices require continuing investment. Physician compensation, advanced practice provider compensation, clinical staff, billing support, rent, malpractice insurance, EMR, marketing, credentialing, compliance, supplies, equipment maintenance, and management time are not optional if they are required to sustain operations. A DCF should also consider capital expenditures and working capital. Equipment-heavy practices may need replacement spending. Practices with long collection cycles may need more working capital. Practices adding providers may need recruiting, credentialing, and ramp-up investment before revenue reaches a stable level.

A model that forecasts revenue growth but omits the staffing, technology, working capital, and equipment needed to support that growth will overstate value.

Scenario analysis and risk

DCF is useful because it can show how value changes under different assumptions. A base case may assume current providers stay, payer contracts renew, and patient demand continues. A downside case may assume a key provider leaves, denials increase, a payer contract changes, or cosmetic demand softens. An upside case may assume successful recruiting, improved collections, or service-line growth. The point is not to produce three arbitrary values. The point is to make risk explicit.

DCF input	Evidence to support it	Specialty notes
Visit/procedure volume	Practice-management reports, schedules, billing data	Cardiology and dermatology may need service-line detail
Provider productivity	Productivity reports, collections by provider, schedules	Replacement risk is often key
Payer mix and reimbursement	Payer contracts, collection reports, CMS PFS context	Primary care value-based arrangements may need separate modeling
Operating expenses	General ledger, staffing, rent, EMR, malpractice, billing	Recurring compliance and billing support is not optional
Capital expenditures	Equipment schedules, lease terms, replacement plans	Cardiology diagnostics may require more equipment analysis
Working capital	A/R aging, supplies, payroll cycle, liabilities	Separate enterprise value from equity value
Terminal value and risk	Market evidence, long-term assumptions, risk factors	Avoid unsupported terminal multiples

Asset Approach, Working Capital, and Enterprise-to-Equity Bridge

When the asset approach matters more

The asset approach can become more important when earnings are weak, the practice is early-stage, the practice is distressed, tangible assets are material, or the transaction is primarily an asset sale. A cardiology practice with diagnostic equipment may require more asset analysis than a low-equipment practice. A dermatology clinic may have lasers, equipment, supplies, and leasehold improvements that matter. A primary care practice may have less expensive equipment but meaningful working capital, receivables, software, and payer contract considerations.

Book value is rarely the full story for a profitable going-concern medical practice. Patient records, assembled workforce, systems, trade name, websites, phone numbers, payer relationships, and practice infrastructure may create intangible value. But ignoring tangible assets and liabilities can be just as problematic as ignoring goodwill.

Goodwill and intangible assets

Goodwill is not automatically transferable. Patient loyalty, referral relationships, and reputation may be tied to individual physicians. A buyer may pay for systems and recurring demand, but it may discount personal goodwill if the physician owner is leaving or reducing time. A valuation should consider retention agreements, transition plans, provider depth, management systems, patient communication, and whether the practice’s brand stands apart from one individual.

The market approach may capture goodwill if comparable transactions are truly comparable. A DCF may capture goodwill through expected future cash flows. The asset approach may identify tangible support. The reconciliation should avoid double counting goodwill while ensuring that real intangible value is not ignored.

Enterprise value to equity value bridge

Bridge item	Direction	Why it matters
Enterprise value indication from DCF or market approach	Starting point	Value of operations before financing and deal-specific adjustments
Add excess cash if included in deal	Add	Cash may or may not transfer depending on terms
Subtract interest-bearing debt and equipment loans	Subtract	Debt reduces equity proceeds if assumed or paid off
Adjust for target working capital	Add/Subtract	A/R, supplies, payroll, and payables affect delivered balance sheet
Subtract payer recoupments or known liabilities if applicable	Subtract	Known obligations reduce economic value
Adjust for excluded assets or retained liabilities	Add/Subtract	Real estate, equipment, or liabilities may be outside the practice deal
Consider earnouts, rollover equity, seller notes separately	Separate analysis	Headline value may not equal cash at closing
Equity value or estimated transaction proceeds	Result	Owner-level value after adjustments

What Documents a Medical Practice Owner Should Prepare

Financial and tax records

Owners can improve valuation support by preparing records before negotiations begin. Core financial records include tax returns, profit-and-loss statements, balance sheets, general ledger detail, monthly revenue and expense trends, payroll, owner compensation and distributions, debt schedules, bank statements if needed, and accounts receivable aging. The records should reconcile as closely as possible to practice-management data and tax filings.

Clean records make adjusted EBITDA more credible. They also reduce the chance that a buyer or appraiser will apply a larger risk adjustment because of uncertainty.

Billing, payer, and productivity records

Billing and payer data are central to medical practice valuation. Owners should prepare payer mix, CPT or service-line revenue, charges, collections, write-offs, denials, accounts receivable aging, provider productivity, visit volume, schedules, and contract summaries. If the practice has value-based care, capitation, shared savings, chronic care management, or other nontraditional revenue, the owner should prepare contracts, attribution reports, quality reports, and revenue calculations.

CMS payment resources provide reimbursement context, but the valuation needs practice-specific data (Centers for Medicare & Medicaid Services, n.d.-b). A practice that cannot explain revenue by payer, provider, service line, and collection pattern will have a harder time supporting a strong valuation conclusion.

Provider, staffing, and legal/compliance records

Provider and staffing records include employment agreements, independent contractor agreements, compensation plans, restrictive covenants where applicable, provider schedules, staffing rosters, malpractice coverage, recruiting activity, turnover history, and retention plans. Legal and compliance records may include leases, vendor contracts, payer contracts, compliance policies, payer correspondence, billing audits, and documentation of referral-sensitive arrangements. The appraiser does not replace healthcare counsel, but the valuation process benefits when these materials are organized.

Specialty KPI package

Cardiology owners should prepare procedure mix, diagnostic utilization, equipment schedules, referral sources, hospital relationship information, payer mix, and provider productivity. Dermatology owners should prepare medical, surgical, Mohs, pathology, cosmetic, and retail revenue detail; patient recurrence; provider productivity; patient acquisition data; and quality or registry documentation where relevant. Primary care owners should prepare patient panels, payer contracts, value-based arrangements, clinician retention, quality metrics, telehealth usage, care coordination data, and patient churn or retention measures.

Category	Documents and data	Why appraisers ask for it
Financial statements	Tax returns, P&L, balance sheet, general ledger, monthly trends	Normalize EBITDA and evaluate sustainability
Billing and collections	Payer mix, CPT/service-line reports, A/R aging, denials, write-offs	Understand revenue quality and reimbursement risk
Provider productivity	Provider schedules, productivity, collections by provider	Evaluate replacement risk and compensation normalization
Payer contracts	Commercial contracts, Medicare/Medicaid participation, capitation or value-based terms	Forecast revenue and risk
Staffing and compensation	Employment agreements, compensation plans, payroll detail	Normalize EBITDA and analyze retention
Assets and liabilities	Equipment schedules, debt, leases, inventory, software, supplies	Support asset approach and EV-to-equity bridge
Compliance and legal	Policies, audits, payer correspondence, referral-sensitive arrangements	Identify risk areas for counsel and valuation assumptions
Specialty data	Cardiology, dermatology, or primary-care KPI package	Improve comparability and forecast support

Practical Steps to Improve Valuation Support Before a Sale or Financing

Improve EBITDA quality without aggressive add-backs

Owners often try to maximize value by maximizing add-backs. A better strategy is to improve credibility. Clean up the chart of accounts. Separate personal, nonrecurring, and owner-specific expenses. Document related-party rent. Track revenue and profitability by provider, service line, site, payer, and procedure category where feasible. Reconcile billing reports to accounting records. Normalize owner compensation with support. Buyers usually prefer credible EBITDA to inflated EBITDA.

Reduce transferability risk

Value improves when the buyer can see that cash flow is not dependent on one person. Build provider retention plans, document workflows, decentralize referral relationships, strengthen management systems, cross-train staff, and reduce dependence on a single owner physician. Make sure patient communications, phone numbers, websites, reviews, payer contracts, leases, and key systems are controlled by the practice rather than by an individual whenever legally and practically appropriate.

Strengthen data quality

Data quality is a valuation asset. A practice that can produce clean monthly financials, payer mix, collections, denials, productivity, service-line revenue, patient volume, equipment schedules, debt schedules, and working-capital data gives buyers and appraisers more confidence. A practice that cannot produce those records may still have value, but the valuation may require more assumptions and risk adjustments.

Use professional valuation help before negotiations

A professional valuation can help owners understand value before a buyer frames the negotiation. It can also help partners, attorneys, CPAs, lenders, and advisers discuss the same economic picture. If you are preparing to sell, buy, finance, restructure, or plan around a cardiology, dermatology, primary care, or other medical practice, Simply Business Valuation can prepare a professional, source-supported business valuation or business appraisal that explains adjusted EBITDA, valuation methods, market approach evidence, discounted cash flow assumptions, asset approach considerations, and major risk factors.

Common Medical Practice Valuation Mistakes

Mistake 1: Applying a public multiple without reading the fine print

Public articles can be useful for background, but they often omit the facts that determine whether a multiple is relevant: transaction population, EBITDA definition, buyer type, deal structure, provider retention, working capital, rollover equity, earnouts, and specialty mix. American Healthcare Appraisal’s article title captures the right caution: EBITDA multiples and gross income multipliers are only a starting point in medical practice valuation (American Healthcare Appraisal, n.d.). The same caution applies to any public range. It may help frame questions; it should not replace a practice-specific valuation.

Mistake 2: Ignoring physician-owner compensation

Owner compensation can make EBITDA look too high or too low. If the owner underpays themselves, reported EBITDA may overstate transferable cash flow. If the owner runs discretionary expenses through the practice, reported EBITDA may understate sustainable cash flow. The adjustment should be supportable either way.

Mistake 3: Treating all revenue as equally durable

Revenue differs by payer, provider, service line, location, patient relationship, referral source, and collection quality. High revenue with weak collections, high denials, concentrated referrals, or uncertain payer contracts may be riskier than lower revenue with consistent collections and stable patient demand.

Mistake 4: Double counting goodwill

If goodwill benefits are already reflected in forecast cash flows, adding a separate goodwill value can double count. If the market approach already captures going-concern value, separately adding all intangible assets may overstate value. If the asset approach is used alone, however, it may miss transferable goodwill. Reconciliation matters.

Mistake 5: Ignoring healthcare counsel

A valuation is not a legal compliance opinion. Healthcare counsel should review Stark Law, Anti-Kickback Statute, compensation arrangements, referral-sensitive structures, management services, leases, and transaction terms where relevant. CMS and OIG sources can provide background, but legal interpretation belongs with counsel (Centers for Medicare & Medicaid Services, n.d.-a; Office of Inspector General, 2021).

Frequently Asked Questions

1. What is the best way to value a medical practice?

The best way is to start with the assignment definition and normalized cash flow, then apply the valuation methods that fit the facts. A professional business valuation usually considers the income approach, discounted cash flow where forecasts are important, the market approach where comparable evidence is reliable, and the asset approach where tangible assets, working capital, or weak earnings matter. The conclusion should reconcile the methods rather than mechanically average them.

2. Can I value a cardiology, dermatology, or primary care practice using a simple EBITDA multiple?

A simple EBITDA multiple can be a useful shorthand, but it is risky as a standalone valuation. The practice’s EBITDA must be normalized, and the selected multiple must be supported by comparable transactions or market evidence. Specialty, scale, payer mix, provider retention, deal terms, buyer type, and risk all matter.

3. What is adjusted EBITDA for a physician practice?

Adjusted EBITDA is EBITDA after supportable normalization adjustments. Common areas include physician-owner compensation, associate provider economics, nonrecurring expenses, rent normalization, payer or billing corrections, and documented discretionary items. Recurring costs needed to sustain operations, such as billing, compliance, EMR, malpractice, staffing, and marketing, should not be casually added back.

4. Why do cardiology practices need different valuation analysis?

Cardiology may involve procedure mix, diagnostic services, equipment, hospital relationships, referral sources, payer mix, and provider capacity. Those factors can affect EBITDA quality, capital expenditures, working capital, regulatory sensitivity, and market comparability. Cardiology consolidation research can provide market context, but it does not establish a universal cardiology multiple.

5. Why do dermatology practices need different valuation analysis?

Dermatology practices can include medical dermatology, surgical dermatology, Mohs, pathology, cosmetic procedures, retail products, and recurring patient demand. The valuation should analyze service-line profitability, provider dependence, cosmetic cyclicality, patient acquisition, and transferability of goodwill. Private-equity activity in dermatology is market context, not a valuation conclusion for every practice.

6. Why do primary care practices need different valuation analysis?

Primary care often depends on patient panels, continuity, payer contracts, clinician retention, care coordination, quality metrics, and value-based or capitated arrangements where applicable. The valuation may require more attention to patient retention, contract durability, staffing stability, and DCF scenarios than to procedure intensity.

7. Which valuation method is best for a medical practice?

No method is always best. The income approach and discounted cash flow are useful when future cash flow can be forecast with support. The market approach is useful when comparable transactions or market data are reliable. The asset approach matters when assets, liabilities, working capital, or weak earnings are important. A credible business appraisal reconciles the evidence.

8. How does discounted cash flow apply to physician practices?

A DCF model forecasts future cash flow based on visits, procedures, provider productivity, payer mix, collections, staffing, compensation, rent, malpractice, EMR, capital expenditures, working capital, and risk. It can test scenarios for provider departures, payer changes, referral shifts, cosmetic demand, patient churn, or value-based contract performance.

9. When is the market approach reliable for medical practice valuation?

The market approach is more reliable when transaction evidence is comparable by specialty, size, geography, payer mix, service line, provider model, buyer type, EBITDA definition, deal structure, and transaction date. It is less reliable when the appraiser only has broad healthcare-services ranges or headline multiples without terms.

10. When does the asset approach matter for a medical practice?

The asset approach matters when equipment, receivables, working capital, inventory, software, leases, debt, and liabilities are material. It may receive more weight for low-profit, distressed, start-up, or asset-heavy practices. Even profitable going concerns need an asset and liability review to bridge enterprise value to equity value.

11. How do Stark Law and Anti-Kickback concerns affect medical practice valuation?

They can affect valuation because physician practice transactions may involve referrals, compensation, management services, leases, or other healthcare relationships. CMS and OIG materials provide high-level background on physician self-referral and fraud-and-abuse laws, but transaction structure and legal compliance should be reviewed by healthcare counsel. A valuation report is not a legal opinion.

12. What documents should I prepare before ordering a medical practice valuation?

Prepare tax returns, financial statements, general ledger detail, monthly revenue and expense reports, payer mix, billing and collections data, A/R aging, denials, provider productivity, compensation agreements, employment agreements, payer contracts, leases, equipment schedules, debt schedules, compliance records, and specialty-specific KPI reports.

13. What is the difference between enterprise value and equity value in a practice sale?

Enterprise value is the value of the operating business before certain financing and deal-specific adjustments. Equity value reflects debt, cash, working capital, liabilities, excluded assets, earnouts, rollover equity, seller notes, and other transaction terms. Sellers should not assume headline enterprise value equals cash proceeds.

14. Can Simply Business Valuation help value my medical practice?

Yes. Simply Business Valuation can assist with a professional medical practice business valuation or business appraisal for owners, buyers, attorneys, CPAs, lenders, and advisers. The report can explain normalized EBITDA, valuation methods, market approach evidence, discounted cash flow assumptions, asset approach considerations, enterprise-to-equity adjustments, and key specialty risks for cardiology, dermatology, primary care, and other physician practices.

References

Agarwal, A., & Orlow, S. J. (2024). An update on private equity acquisitions in dermatology, 2013 to 2022. Journal of the American Academy of Dermatology, 90(2), 446-448. https://pubmed.ncbi.nlm.nih.gov/37863202/

AICPA & CIMA. (2025, June 5). Statement on Standards for Valuation Services (VS Section 100). https://www.aicpa-cima.com/resources/download/statement-on-standards-for-valuation-services-vs-section-100

American Academy of Dermatology. (n.d.). DataDerm. https://www.aad.org/member/practice/dataderm

American Academy of Family Physicians. (2019, December 13). Primary care. https://www.aafp.org/about/policies/primary-care

American College of Cardiology. (2024, July 1). JACC study finds private equity acquisition a growing trend in cardiology. https://www.acc.org/latest-in-cardiology/articles/2024/07/01/12/03/jacc-study-finds-private-equity-acquisition-a-growing-trend-in-cardiology

American Healthcare Appraisal. (n.d.). Medical practice valuation: Why EBITDA multiples and gross income multipliers are only the starting point. https://www.ahca.com/healthcare-insights/medical-practice-valuation-why-ebitda-multiples-and-gross-income-multipliers-are-only-the-starting-point

Bartlett, V. L., Liu, M., Ati, S., Yeh, R. W., Zheng, Z., & Wadhera, R. K. (2024). Private equity acquisitions of outpatient cardiology practices in the United States, 2013-2023. Journal of the American College of Cardiology, 84(10), 953-956. https://pubmed.ncbi.nlm.nih.gov/38955290/

Centers for Medicare & Medicaid Services. (n.d.-a). Physician self-referral. https://www.cms.gov/medicare/regulations-guidance/physician-self-referral

Centers for Medicare & Medicaid Services. (n.d.-b). Physician fee schedule. https://www.cms.gov/medicare/payment/fee-schedules/physician

FOCUS Investment Banking. (2025, November 26). Medical practice valuation 2026 guide. https://focusbankers.com/medical-practice-valuation/

International Valuation Standards Council. (n.d.). Standards. https://ivsc.org/standards/

Medical Group Management Association. (n.d.-a). MGMA DataDive provider compensation data. https://www.mgma.com/datadive/provider-compensation

Medical Group Management Association. (n.d.-b). MGMA DataDive financials and operations data. https://www.mgma.com/datadive/financials-and-operations-data

Memon, R., Memon, A., Francis, J., & Konda, S. (2022). Trends in debt valuations of private equity-backed dermatology groups before and during the COVID-19 pandemic. JAMA Dermatology, 158(4), 395-403. https://pmc.ncbi.nlm.nih.gov/articles/PMC8908222/

National Association of Certified Valuators and Analysts. (n.d.). Professional standards and ethics. https://www.nacva.com/standards

Office of Inspector General. (2021, September 1). Fraud & abuse laws. U.S. Department of Health and Human Services. https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/

Singh, Y., Radhakrishnan, N., Adler, L., & Whaley, C. (2025). Growth of private equity and hospital consolidation in primary care and price implications. JAMA Health Forum, 6(1), e244935. https://pubmed.ncbi.nlm.nih.gov/39820388/

Singh, Y., Reddy, M., & Whaley, C. (2024). Trends in private equity consolidation in cardiovascular care. JAMA Health Forum, 5(6), e241478. https://pmc.ncbi.nlm.nih.gov/articles/PMC11179124/

Tan, S., Seiger, K., Renehan, P., & Mostaghimi, A. (2019). Trends in private equity acquisition of dermatology practices in the United States. JAMA Dermatology, 155(9), 1013-1021. https://pubmed.ncbi.nlm.nih.gov/31339521/

The Appraisal Foundation. (n.d.). USPAP®. https://appraisalfoundation.org/products/uspap

ValuSource. (n.d.). Goodwill Registry. https://www.valusource.com/products/business-appraiser-databases/goodwill-registry/

Zhu, J. M., Huntington, A., Giuriato, M., Polsky, D., & Song, Z. (2026). Private equity acquisition of primary care practices: Modest growth in clinicians offset by increased clinician exits. Health Affairs, 45(3), 261-268. https://pubmed.ncbi.nlm.nih.gov/41770993/